Mostrar el registro sencillo del ítem

Artículo

dc.creatorSantos García, Diegoes
dc.creatorDeus Fonticoba, Teresa dees
dc.creatorCores, Carloses
dc.creatorMuñoz, Guillermoes
dc.creatorPaz González, José M.;es
dc.creatorMartínez Miró, Cristinaes
dc.creatorMir Rivera, Pabloes
dc.date.accessioned2022-09-15T16:52:16Z
dc.date.available2022-09-15T16:52:16Z
dc.date.issued2021
dc.identifier.citationSantos García, D., Deus Fonticoba, T.d., Cores, C., Muñoz, G., Paz González, J.M.;., Martínez Miró, C. y Mir Rivera, P. (2021). Predictors of clinically significant quality of life impairment in Parkinson’s disease. NPJ Parkinson's disease, 7 (118), 1-10.
dc.identifier.issn2373-8057es
dc.identifier.urihttps://hdl.handle.net/11441/137113
dc.description.abstractQuality of life (QOL) plays an important role in independent living in Parkinson’s disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors of QoL impairment in PD patients from a Spanish cohort. PD patients recruited from 35 centers of Spain from the COPPADIS cohort from January 2016, to November 2017, were followed up during 2 years. Health-related QoL (HRQoL) and global QoL (GQoL) were assessed with the 39-item Parkinson’s disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8), respectively, at baseline (V0) and at 24 months ± 1 month (V2). Clinically significant QoL impairment was defined as presenting an increase (PDQ-39SI) or decrement (EUROHIS-QOL8) at V2 ≥ 10% of the score at baseline (V0). A comparison with a control group was conducted for GQoL. GQoL didnot change significantly in PD patients (N = 507; p = 0.686) or in the control group (N = 119; p = 0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 ± 8.5 years old; 58.8% males; N = 500) by 21.6% (from 16.7 ± 13 to 20.3 ± 16.4; p < 0.0001) at V2. Ninety-three patients (18.6%) presented a clinically significant HRQoL impairment at V2. To be younger (OR = 0.896; 95% CI 0.829–0.968; p = 0.006), to be a female (OR = 4.181; 95% CI 1.422–12.290; p = 0.009), and to have a greater increase in BDI-II (Beck Depression Inventory-II) (OR = 1.139; 95% CI 1.053–1.231; p = 0.001) and NMSS (Non-Motor Symptoms Scale) (OR = 1.052; 95% CI 1.027–1.113; p < 0.0001) total scores from V0 to V2 were associated with clinically significant HRQoL impairment at the 2-year follow-up (Hosmer–Lemeshow test, p = 0.665; R2 = 0.655). An increase in ≥5 and ≥10 points of BDI-II and NMSS total score at V2 multiplied the probability of presenting clinically significant HRQoL impairment by 5 (OR = 5.453; 95% CI 1.663–17.876; p = 0.005) and 8 (OR = 8.217; 95% CI, 2.975–22.696; p = 0.002), respectively. In conclusion, age, gender, mood, and non-motor impairmentwere associated with clinically significant HRQoL impairment after the 2-year follow-up in PD patients.es
dc.formatapplication/pdfes
dc.format.extent10es
dc.language.isoenges
dc.publisherSpringeres
dc.relation.ispartofNPJ Parkinson's disease, 7 (118), 1-10.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectPredictorses
dc.subjectQuality of lifees
dc.subjectParkinsones
dc.titlePredictors of clinically significant quality of life impairment in Parkinson’s diseasees
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Medicinaes
dc.relation.publisherversionhttps://www.nature.com/articles/s41531-021-00256-wes
dc.identifier.doi10.1038/s41531-021-00256-wes
dc.journaltitleNPJ Parkinson's diseasees
dc.publication.volumen7es
dc.publication.issue118es
dc.publication.initialPage1es
dc.publication.endPage10es

FicherosTamañoFormatoVerDescripción
281.pdf1.064MbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Attribution-NonCommercial-NoDerivatives 4.0 Internacional